Code intelligence

FDA-NDA210365 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance referencing code FDA-NDA210365.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated
0

Critical

0%

1

High

100%

0

Routine

0%

0

Low

0%

New this month

+1

alerts added in last 30 days

Effective soon

no upcoming deadlines

FDA Approval: EPIDIOLEX (CANNABIDIOL) — Type 1 - New Molecular Entity

Policy FDA-NDA210365 · Neurology

High

Epidiolex, an oral cannabidiol solution, will fall under Medicare Part D for billing purposes. As it is an orphan drug, it may also have specific considerations for reimbursement and coverage. No J-co